US Cases / Year
~35,000
Approximately 35,000 new cases of multiple myeloma diagnosed annually in the United States, representing ~1.8% of all new cancer diagnoses.[1]
What Is It
Definition, mechanism, and the clinical reality of multiple myeloma at end of life. What the hospice team needs to understand on day one.
Median Age at Diagnosis
69 yrs
Predominantly older adults. Treatment intensity must be calibrated to age, frailty, and comorbidity — particularly renal function and cardiac reserve.[1]
5-Year Survival, All Stages
~57%
Dramatically improved with modern triplet/quadruplet therapy and stem cell transplant — but not cured in the vast majority. The median is pulled upward by younger, transplant-eligible patients.[2]
Bone Lesion Prevalence
~80%
Approximately 80% of myeloma patients have osteolytic bone lesions at diagnosis — the defining clinical feature that causes the most suffering at end of life.[3]
Multiple myeloma is a cancer of plasma cells — the antibody-producing cells of the immune system. In myeloma, a single clone of malignant plasma cells proliferates in the bone marrow, producing large quantities of a nonfunctional monoclonal immunoglobulin (M-protein) while crowding out normal blood cell production. The disease is defined by what those malignant plasma cells do to the body: they release osteoclast-activating factors that dissolve bone without rebuilding it, produce abnormal light chains that deposit in the renal tubules and destroy kidney function, suppress normal immunoglobulin production leaving patients profoundly immunocompromised, and replace healthy marrow causing progressive anemia and thrombocytopenia.[2]
Four things define the end-stage myeloma patient arriving at hospice: bone pain that waxes and wanes with fractures and spinal collapse, hypercalcemia that clouds the mind and paralyzes the gut, renal failure from light chain deposition and recurrent dehydration, and infections from an immune system that has been suppressed by both the disease and by years of immunosuppressive treatment. All four may be present simultaneously. These patients have typically received 5–7 prior lines of therapy — more than almost any other cancer diagnosis in hospice. They have been fighting for years, often a decade or more, cycling through remissions and relapses. The treatment landscape they leave behind — proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, CAR-T cells, bispecific antibodies — is vast. The hospice clinician must understand that landscape to meet the patient where they are.[4]
🧭 Clinical framing
Multiple myeloma is a cancer of the skeleton as much as it is a cancer of the blood. The osteolytic lesions do not heal — myeloma uniquely uncouples bone resorption from bone formation, so every lesion is permanent and cumulative. By the time a myeloma patient reaches hospice, their skeleton is a minefield of lytic lesions, compression fractures, and areas of critical weakness. Every transfer, every repositioning, every cough carries fracture risk. The hospice team must internalize this: gentleness is not optional — it is clinical. The bone pain that dominates these patients' lives is not just nociceptive — it is a constant reminder of structural vulnerability. Treat the pain aggressively, handle the body carefully, and never forget that the skeleton you cannot see is the dominant clinical landscape of this disease.
"Myeloma patients walk into hospice carrying ten years of treatment on their backs. They know more about their disease than most clinicians who will care for them. They've been through regimens you've never heard of. They've been told 'there's one more thing to try' so many times that they don't fully trust that this time is different. Your job isn't to explain their disease to them — it's to prove that you understand what they've been through, and that the bone pain that wakes them up at 3 AM is going to be managed like it matters. Because it does."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, staging, CRAB/SLiM-CRAB criteria, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Diagnostic Workup
- SPEP & Immunofixation: Identifies and characterizes the M-protein — the abnormal monoclonal immunoglobulin produced by myeloma cells. Quantifies the M-spike for disease monitoring.[5]
- Serum Free Light Chains (sFLC): Kappa and Lambda — elevated ratio indicates disease activity. Critical monitoring tool, especially in light-chain-only myeloma and oligosecretory disease.[5]
- 24-Hour Urine (UPEP): Detects Bence-Jones protein. Light chain deposition causes direct renal tubular damage — the mechanism of myeloma kidney.[6]
- Bone Marrow Biopsy & Aspiration: Gold standard — ≥10% clonal plasma cells defines the diagnosis. FISH cytogenetics: del(17p), t(4;14), t(14;16), t(11;14), gain(1q) — critical for prognosis and treatment selection.[7]
- Skeletal Imaging: Whole-body low-dose CT preferred over plain skeletal survey — detects lytic lesions with higher sensitivity. PET-CT for equivocal cases. MRI for spinal cord compression evaluation.[3]
- CBC & CMP: Anemia from marrow replacement (normocytic, normochromic), thrombocytopenia in advanced disease. Calcium, creatinine, albumin — CRAB criteria components.
What to Look for in Hospice Records
- High-risk cytogenetics: del(17p) is the single worst prognostic marker. t(4;14) and t(14;16) are intermediate-high risk. Standard risk [t(11;14), hyperdiploidy] carries better prognosis.[7]
- M-protein / sFLC trend: Rising M-protein or rapidly increasing free light chain ratio signals active disease progression.
- Renal function trend: Creatinine, GFR — myeloma kidney is irreversible in most end-stage patients. Trend determines medication dosing for all hospice drugs.
- Prior treatment lines & agents: PIs (bortezomib, carfilzomib, ixazomib), IMiDs (thalidomide, lenalidomide, pomalidomide), anti-CD38 (daratumumab, isatuximab), BCMA-directed (CAR-T, bispecifics, ADCs), alkylators. Count of prior lines predicts remaining treatment options.[8]
- ASCT history: Whether performed, when, tandem vs single — informs disease trajectory understanding.
- Vertebral lesion locations: Know which vertebral levels have lytic disease — this is your spinal cord compression risk map.
- ECOG trajectory over last 3 months: Rate of functional decline predicts prognosis more reliably than any lab value.
📊 CRAB & SLiM-CRAB Criteria
CRAB criteria for active myeloma requiring treatment: Calcium >11 mg/dL, Renal impairment (creatinine >2 mg/dL or CrCl <40 mL/min), Anemia (Hgb <10 g/dL), Bone lesions (≥1 lytic lesion on imaging). SLiM-CRAB adds: Sixty percent clonal plasma cells, Light chain ratio ≥100, MRI lesions ≥2. ISS staging (I, II, III) based on beta-2 microglobulin and albumin — ISS III with high-risk cytogenetics (R-ISS III) carries the worst prognosis.[5]
💡 For families
Your loved one's myeloma was diagnosed through blood tests that found abnormal proteins, a bone marrow test, and imaging that showed bone damage. By the time of hospice enrollment, all of this diagnostic work is complete. The focus now is entirely on comfort — managing bone pain, preventing fractures, treating infections, and keeping your person as comfortable and present as possible. You do not need to understand the lab numbers. You need to know that the team does.
Causes & Risk Factors
MGUS/SMM progression, racial disparities, Agent Orange, and germline considerations. Relevant for family conversations and answering "why did this happen?"
Precursor Conditions & Progression
- MGUS (Monoclonal Gammopathy of Undetermined Significance): Present in ~3% of adults over 50. Progresses to myeloma at ~1%/year. Most myeloma is preceded by MGUS — the patient may have had an abnormal protein for years before diagnosis.[9]
- Smoldering Multiple Myeloma (SMM): Intermediate between MGUS and active myeloma. Higher progression rate — ~10%/year in the first 5 years. Active surveillance standard; early treatment under investigation.[9]
- Age: Incidence rises steeply after 60. Median diagnosis age 69 years.
- Male sex: Slightly higher incidence (1.4:1 male-to-female ratio).
- Obesity: Established risk factor — adipokine-mediated plasma cell stimulation (RR ~1.2 per 5 kg/m² BMI increase).[10]
Hereditary & Environmental
- African American race: Black Americans have twice the incidence of myeloma compared to white Americans and are diagnosed at younger ages — one of the most striking racial disparities in cancer epidemiology.[11]
- Family history: First-degree relative with myeloma or MGUS confers ~2–4× elevated risk.
- Agent Orange exposure: Recognized VA benefit — important for veteran patients. Screen all veterans for exposure history.[12]
- Prior radiation exposure: Modest increased risk in occupational and medical radiation settings.
- Pesticide/agricultural chemical exposure: Some epidemiological associations, particularly with organochlorines.
- Germline: Familial myeloma is rare but exists. BRCA2, ATM, and DNA repair gene variants have been associated with increased myeloma risk in family studies.[10]
⚖ Racial Disparity — Read This
Black Americans are diagnosed with myeloma at twice the rate of white Americans, at younger ages, and with higher tumor burden at diagnosis — yet they are less likely to receive stem cell transplant, less likely to receive novel agent combinations, and have historically had worse survival outcomes. Recent data from centers with equal access (VA system, clinical trials) show that Black Americans actually have better survival when treated with equal access to modern therapy — the disparity is access-driven, not biology-driven. When you walk into the home of a Black patient dying of myeloma, understand that the disease that is killing them may have progressed faster than it needed to because of barriers encountered years before hospice enrollment. Treat them with the precision and advocacy that gap demands.[11]
❤️ For families: "Why did this happen?"
Multiple myeloma is not caused by anything your loved one did or didn't do. It begins with a small change in a single immune cell — often years or decades before any symptoms appear. Most people with the earliest form (MGUS) never develop myeloma at all. The reasons why some do and some don't are still being studied. There is no lifestyle choice that caused this. For veterans: Agent Orange exposure is a recognized risk factor, and VA benefits apply. If your family member served in Vietnam or areas with Agent Orange, ensure they have VA benefit documentation.
⚕ Clinician note: Genetic counseling
Familial myeloma clusters are rare but documented. If the patient has first-degree relatives with myeloma, MGUS, or other plasma cell neoplasms, genetic counseling referral is appropriate even at hospice enrollment — this information can benefit surviving family members. Germline BRCA2 and ATM testing may also have implications for cancer risk in offspring.[10]
Treatments & Procedures
What disease-directed treatments this patient may have received or may still be receiving. Understanding 5–7 prior lines helps anticipate complications and interpret the trajectory.
Myeloma patients arrive at hospice having been through more lines of therapy than almost any other cancer diagnosis. The modern myeloma treatment landscape includes proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, CAR-T cell therapy, bispecific antibodies, and autologous stem cell transplant. Understanding what a patient has received — and how they tolerated it — is essential to anticipating the complications they carry into hospice care.[13]
Induction & Transplant
- VRd (bortezomib + lenalidomide + dexamethasone): Standard triplet induction. Know bortezomib → peripheral neuropathy (persists indefinitely). Know lenalidomide → cytopenias, VTE risk.[13]
- Dara-VRd (daratumumab + VRd): Quadruplet induction — PERSEUS and GRIFFIN trials. Daratumumab infusion reactions, prolonged immunosuppression.[14]
- ASCT (Autologous Stem Cell Transplant): Standard consolidation for transplant-eligible patients. Median PFS 40–55 months with maintenance. Know if performed and when — informs disease trajectory.[15]
- Maintenance (lenalidomide): Post-ASCT standard. Extends PFS significantly. May be continued into hospice if tolerated and goals include disease control.
Relapsed/Refractory & Novel Agents
- Anti-CD38 (daratumumab, isatuximab): Used in first and subsequent lines. Prolonged B-cell aplasia and infection risk.[16]
- Pomalidomide + dex ± daratumumab: Standard in IMiD-refractory disease. Oral, manageable toxicity.
- Carfilzomib combinations (KRd, ASPIRE): Higher cardiac toxicity than bortezomib. Screen for cardiac history.[17]
- BCMA-directed CAR-T (ide-cel/Abecma, cilta-cel/Carvykti): FDA approved for ≥4 prior lines. High response rates (60–80%). CRS, neurotoxicity, prolonged cytopenias.[18]
- Bispecific antibodies (teclistamab, elranatamab, talquetamab): Off-the-shelf. High response in heavily pretreated. Ongoing infections from T-cell engagement and B-cell aplasia.[19]
- Selinexor (XPO1 inhibitor): Penta-refractory option. Significant toxicity — profound fatigue, nausea, weight loss, cytopenias.[20]
Palliative Procedures in Myeloma
- Bisphosphonates (zoledronic acid): Monthly or quarterly — reduces skeletal events. May continue in hospice as fracture prevention is comfort care. Requires GFR >30 — use denosumab if below.[21]
- Denosumab (XGEVA): Preferred in renal impairment — no dose adjustment required. Monthly SQ. Reduces SREs in myeloma (20.4-MRC IX).[22]
- Kyphoplasty/Vertebroplasty: For vertebral compression fractures causing severe pain — hospice-compatible. Pain relief within 24–48 hours. Restores functional capacity.[23]
- Palliative radiation: Single fraction 8 Gy for painful bone lesions — highly effective in myeloma, hospice-compatible.[24]
- IVIG: For recurrent severe infections from myeloma immunoparesis — consider if infection is the primary driver of decline and consistent with goals.[25]
When Therapy Makes Sense
Evidence-based criteria for continuing disease-directed therapy in myeloma. This is not about giving up or holding on — it's about reading the data correctly.
Myeloma is a disease of serial relapses and serial salvage. More than almost any other cancer, there are patients who derive genuine clinical benefit from treatment even deep into their disease course. The modern era of BCMA-directed therapies — CAR-T and bispecific antibodies — has created meaningful response rates even in patients who have failed 5–7 prior lines. The key question is not "is there another treatment?" (there almost always is) but "will this patient benefit more than they are burdened?" That requires honest assessment of performance status, renal function, infection trajectory, and the patient's own goals.[18]
- 01BCMA-directed therapy with ECOG 0–2 and actionable target: CAR-T (ide-cel, cilta-cel) or bispecific antibodies (teclistamab, elranatamab) achieve response rates of 60–80% even in heavily pretreated patients. In a disease where the median prior lines at hospice enrollment is 5–7, these represent genuinely meaningful options in appropriate patients.[18][19]
- 02Daratumumab-based combination, ECOG 0–1, after 1–3 prior lines with IMiD-refractory disease: Response rates >80%. Manageable toxicity profile. DPd (daratumumab-pomalidomide-dexamethasone) is well-tolerated and can be continued with good quality of life.[16]
- 03Kyphoplasty or vertebroplasty for vertebral compression fracture: Even in hospice-eligible patients, this comfort intervention deserves discussion. Significant pain relief within 24–48 hours. Can restore functional capacity and reduce opioid requirements dramatically.[23]
- 04Palliative radiation for painful bone lesion: Single fraction 8 Gy — highly effective in myeloma, hospice-compatible. Pain response rates of 60–80%. Not disease treatment — comfort care.[24]
- 05Bisphosphonate or denosumab continuation for fracture prevention: Fracture prevention is comfort care even in end-stage disease. Denosumab preferred if GFR <30.[22]
- 06Hypercalcemia treatment (IV fluids + denosumab/bisphosphonate): If hypercalcemia is the primary driver of decline and treatment would restore meaningful function — treat it. A patient who looks like they are dying from hypercalcemia may be talking to their family by Friday.
- 07Oral targeted therapy continuation: Myeloma is one of the few cancers where oral targeted therapy (ixazomib, lenalidomide) may be continued in hospice patients who are tolerating it well and whose goals include disease control. The conversation is nuanced and must be individualized.
When It Doesn't
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.
Myeloma is one of the most under-referred cancers to hospice. The serial availability of new agents — and the genuine response rates they achieve — creates a treatment treadmill that can continue far past the point of net clinical benefit. The oncologist's reflexive "there's one more thing we can try" is often technically true but clinically misleading. The hospice clinician must understand the thresholds below to anchor honest conversation.[4]
- 01Penta-refractory myeloma: Refractory to ≥1 IMiD, ≥1 PI, anti-CD38 antibody, anti-BCMA agent, and alkylator. Median OS 3–6 months. No established effective salvage regimen remains. This is the clearest hospice-appropriate threshold in myeloma.[20]
- 02ECOG ≥3: No evidence of survival benefit from further systemic therapy at ECOG ≥3 in myeloma. Treatment toxicity outweighs potential benefit. Focus shifts entirely to symptom management.
- 03Post-CAR-T relapse within 6 months: Very poor prognosis. Bispecific antibodies may provide additional months but are rarely curative in this setting. Goals-of-care conversation is essential.[18]
- 04Renal failure requiring dialysis from myeloma kidney: Median OS 1–2 years on dialysis in myeloma. Goals-of-care conversation about dialysis continuation is a primary clinical task at hospice enrollment. Dialysis burden, transport requirements, and quality of life must be weighed explicitly.[6]
- 05Pathologic fracture of weight-bearing bone without surgical candidacy: Pain may be refractory without surgical stabilization. This is a comfort crisis that defines the hospice enrollment timing in many myeloma patients.
- 06Hypercalcemia refractory to bisphosphonate/denosumab with declining renal function: Uremic trajectory superimposed on disease progression. Estimated survival <3 months.
- 07Patient goals shift to comfort and presence after years of fighting: When a fully informed patient who has been through 5–7 lines of therapy says "I'm done," honor that clarity without hesitation.
📋 The treatment-exhaustion conversation
Myeloma patients have often been told "there's one more thing to try" many times. By the time they reach hospice they may not trust that this time is truly different. Acknowledge that history. Acknowledge that every prior hope was real. And then be honest about what the current clinical picture actually means — without using "there's nothing more we can do." Because that is never true in myeloma. The question is whether what remains to be done is disease treatment or comfort treatment, and those are not the same thing. Say it exactly that way.
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches for myeloma. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Kyphoplasty / Vertebroplasty
Grade ABalloon kyphoplasty — interventional radiology referral; outpatient or short stay
Randomized evidence supports vertebral augmentation for pain relief in myeloma-related vertebral compression fractures. Pain relief occurs within 24–48 hours. Even in hospice-eligible patients, this procedure can dramatically reduce pain and restore functional mobility. Discuss with interventional radiology before the fracture becomes a crisis. Hospice-compatible if consistent with patient goals.[23]
Palliative Radiation for Bone Lesions
Grade ASingle fraction 8 Gy to painful bone lesion — radiation oncology referral
Pain response rates of 60–80% in myeloma bone lesions with single-fraction radiation. Previously irradiated sites can be re-treated with adapted protocols. Refer to radiation oncology at enrollment for any patient with severe localized bone pain. This is comfort care, not disease treatment.[24]
Denosumab for Bone Protection in Renal Impairment
Grade ADenosumab (XGEVA) 120 mg SQ monthly
Does not require dose adjustment for renal impairment — unlike zoledronic acid. Monthly subcutaneous injection. Reduces skeletal-related events including pathologic fractures. Fracture prevention is comfort care even in end-stage disease. Preferred over bisphosphonates when GFR <30. Also treats hypercalcemia of malignancy.[22]
Acupuncture for Bone Pain & Neuropathy
Grade BTwice weekly for 4–8 weeks, then weekly maintenance
Cancer bone pain responds to acupuncture in multiple RCTs. Chemotherapy-induced peripheral neuropathy from bortezomib and thalidomide specifically responds to acupuncture in several trials. Particularly valuable because pharmacological neuropathy options are limited by renal function in myeloma. Safe, well-tolerated. Avoid in areas of known lytic bone disease. Caution with thrombocytopenia — platelet count >20,000 generally safe.[26]
Hypercalcemia Comfort Management Protocol
Grade BNS 1–2 L over 4–6 hours (SQ if IV not feasible) + denosumab 120 mg SQ or zoledronic acid 4 mg IV (if GFR >30)
Mild to moderate hypercalcemia (11–13 mg/dL) causes confusion, nausea, constipation, polyuria, and fatigue — all treatable. Aggressive hydration + bone-modifying agent restores mental clarity and reduces nausea in days. In comfort-focused care, treating hypercalcemia is treating the symptoms. A patient who looks like they are dying on Tuesday may be talking to you by Friday.[27]
Music Therapy & Guided Imagery
Grade B30–60 min sessions, 2–3× weekly; patient-preferred music
Meta-analyses demonstrate reduction in pain perception, anxiety, and opioid requirements in cancer patients. Particularly beneficial in myeloma patients with chronic bone pain and treatment fatigue. No drug interactions, no renal considerations. Can be delivered by trained music therapists or via patient-curated playlists with guided protocols.[28]
TENS (Transcutaneous Electrical Nerve Stimulation) for Neuropathic Pain
Grade CLow-frequency TENS 20–40 min daily over affected areas
Limited but promising evidence for chemotherapy-induced peripheral neuropathy. Non-invasive, safe, no drug interactions. Reasonable adjunct when gabapentin is limited by renal function and topical agents are insufficient. Avoid over areas with skin breakdown or infection. Avoid electrodes directly over known lytic bone lesions.[26]
Subcutaneous Hydration (Hypodermoclysis)
Grade B500–1500 mL NS or D5-NS SQ over 4–12 hours via butterfly needle in abdomen or thigh
Myeloma patients are chronically dehydrated from hypercalcemia-induced polyuria, reduced oral intake, and renal concentrating defects. Subcutaneous hydration is a hospice-appropriate alternative to IV access. Can be administered at home by trained caregivers. Effective for mild-moderate dehydration and hypercalcemia symptom management. Well-tolerated in the home setting.[29]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to myeloma. Patients will use supplements — this section helps you have the right conversation.
🫘 Renal Warning — Read First
Renal impairment is universal in end-stage myeloma and changes everything. Most herbal supplements are renally cleared or nephrotoxic in concentrated doses. In a patient with GFR <30, what is safe at normal kidney function may accumulate to toxic levels or cause additional renal damage. Additionally, peripheral neuropathy from prior bortezomib or thalidomide means that any herb with neurotoxic potential carries amplified risk. Review every supplement against current GFR, neuropathy severity, and platelet count before recommending.
"Myeloma patients have been taking supplements for years — turmeric, green tea, you name it. They've read the studies. Some of those supplements are now dangerous because the kidneys can't clear them. You have to ask what they're taking, check it against their GFR, and have the honest conversation: 'This was fine when your kidneys were working. It's not fine now.' They'll respect you for knowing the difference."
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Ginger | Grade B | 500–1000 mg/day; reduce in severe renal impairment | Nausea from systemic disease and medication side effects. Anti-emetic properties well-supported. Important for managing multifactorial nausea in myeloma. | Safe at low doses. Minimal drug interactions. Mild antiplatelet — caution if platelets <50K. Reduce dose 50% if GFR <30. |
| Turmeric / Curcumin | Grade C | 500–1000 mg/day standardized extract; LOW dose only | Some anti-myeloma signal via NF-κB pathway in cell lines. Anti-inflammatory. Modest bone pain benefit. | ⚠ CYP3A4 interaction with lenalidomide, pomalidomide, and dexamethasone. Antiplatelet caution in thrombocytopenic patients. Reduce dose in renal impairment. Flag if on any IMiD or steroid. |
| Melatonin | Grade C | 1–5 mg at bedtime | Sleep disruption from bone pain, steroid use, and systemic disease. Safe and well-tolerated. One of the safer supplements in renally impaired myeloma patients. | Minimal drug interactions. May potentiate sedation with benzodiazepines. No significant renal clearance concerns. Safe to recommend. |
| Boswellia / Frankincense | Grade C | 300–500 mg TID standardized extract | Anti-inflammatory. Some bone pain benefit in cancer patients. Particularly appropriate when NSAIDs are contraindicated by renal function. | Safe profile. Minimal renal clearance. No significant drug interactions. One of the more appropriate supplements in myeloma bone pain. |
| Omega-3 Fatty Acids | Grade C | <1 g/day in severe renal impairment | Anti-inflammatory and cachexia benefit. May reduce systemic inflammation contributing to bone pain. | Antiplatelet caution in thrombocytopenic patients. Reduce dose to <1 g/day in GFR <30. Fish oil burps may worsen nausea — enteric-coated preferred. |
🚫 Avoid in Multiple Myeloma
- NSAIDs and COX-2 inhibitors (including "natural" ibuprofen, naproxen, willow bark): Directly nephrotoxic. Absolutely contraindicated in myeloma with any degree of renal impairment. This includes over-the-counter forms. Willow bark (natural salicylate) carries the same risk.[30]
- High-dose Vitamin C (>500 mg/day): Metabolized to oxalate — exacerbates renal tubular damage in myeloma kidney. Increases kidney stone risk in already-compromised kidneys. Low-dose (<250 mg) is acceptable.
- St. John's Wort: Potent CYP3A4 inducer — reduces levels of dexamethasone, lenalidomide, pomalidomide, bortezomib, and virtually every myeloma drug. Absolutely avoid.
- Green Tea Extract (high-dose EGCG): Hepatotoxic at concentrated doses. Interferes with bortezomib efficacy (blocks proteasome inhibition). Do not recommend in any myeloma patient who may still be on PI therapy. Moderate tea drinking (<3 cups/day) is acceptable.
- Kava: Hepatotoxic. Sedative potentiation with opioids and benzodiazepines. Avoid in myeloma patients on multi-drug symptom management regimens.
- Aristolochic acid-containing herbs: Directly nephrotoxic. Banned in many countries but still found in some traditional preparations. Screen any imported herbal products.
- High-dose Calcium supplements: Myeloma patients are prone to hypercalcemia from bone destruction. Exogenous calcium supplementation can precipitate or worsen hypercalcemia. Dietary calcium is sufficient; supplements should be avoided unless ionized calcium is documented low.
- Grapefruit juice (large quantities): CYP3A4 inhibitor — affects dexamethasone metabolism. Small amounts acceptable; avoid regular large-volume consumption.
Timeline Guide
A guide, not a prediction. Every myeloma trajectory is shaped by cytogenetics, treatment history, renal function, and the skeleton's structural integrity.
Myeloma has the widest trajectory range of any hematologic malignancy — from 5–10+ years in standard-risk transplant-eligible patients to 3–6 months in penta-refractory disease. The timeline below maps the typical disease arc from diagnosis through death, with myeloma-specific milestones at each phase. Use this to orient families and calibrate your clinical approach at each stage.[2]
YRS–
MOS
MOS
Newly Diagnosed / Early Remission (5–10+ years)
- Responding to modern triplet/quadruplet induction (VRd, Dara-VRd). Post-ASCT on lenalidomide maintenance. Functionally well — ECOG 0–1.
- Managing steroid effects (mood instability, insomnia, glucose intolerance), neuropathy from bortezomib/thalidomide, fatigue, and the psychological weight of a chronic incurable disease.
- Bone lesions are present but stable. Skeleton is being monitored with imaging. Bisphosphonates or denosumab ongoing.
- Palliative care integration is essentially never offered at this stage and should be. Advance care planning conversations belong here.
MOS–
1 YR
1 YR
Second & Third Relapse — Rotating Through Agents (2–4 years)
- Cycling through daratumumab, pomalidomide, carfilzomib, and other agents. Response rates declining with each line. Toxicity accumulating.
- Bone disease progressing — vertebral compression fractures accumulating. Renal function declining. Infections becoming more frequent.
- The trajectory is still potentially years but is clearly downward. ECOG drifting from 1 to 2.
- Palliative care integration critical at this stage — frequently missed because the patient "still has options." They do, but the options are narrowing.
WKS–
MOS
MOS
Penta-Refractory / Post-CAR-T Relapse — Hospice Transition
- ECOG declining to 2–3. Bone pain requiring regular opioids. Hypercalcemia episodes becoming more frequent and harder to reverse.
- Creatinine rising. Transfusion dependence beginning or increasing. Free light chains rising rapidly.
- Hospice enrollment most appropriate at this phase. The treatment-exhaustion conversation must happen with compassion and honesty.
- The skeleton is the dominant clinical landscape. Fracture risk at every transfer. Spinal cord compression risk with every vertebral lesion.
DAYS–
WKS
WKS
Active Dying — Pre-Active Phase
- Profound bone pain requiring around-the-clock opioids (hydromorphone preferred over morphine given renal failure). Pathologic fracture possible at any time with minimal provocation.
- Hypercalcemia causing somnolence, confusion, and nausea. Decision about whether to continue treating hypercalcemia must be made explicitly.
- Renal failure progressing — uremia contributing to nausea, confusion, myoclonus. Medication doses must be re-evaluated daily.
- SQ medication conversion. Denosumab may be continued SQ for comfort. Transfusion intervals discussed with family in context of goals.
HRS–
DAYS
DAYS
Final Hours
- Uremia dominant if renal failure advanced — may cause myoclonus (treat with midazolam, not more opioid). Somnolence deepening.
- Possible sudden neurological change from spinal cord compression or intracranial plasmacytoma — have midazolam and dexamethasone protocols ready.
- Cheyne-Stokes breathing. Mottling of extremities. Progressive unresponsiveness.
- Bone pain must be managed even in the final hours. Do not allow breakthrough pain in a myeloma patient at the end of life. Continue scheduled opioids. Continue PRN protocol. Comfort is not optional at any stage.
Medications to Anticipate
Symptom-targeted pharmacology for myeloma. What to have in the comfort kit, what to titrate first, and what the evidence supports — all through the lens of myeloma kidney.
🫘 Renal Dosing — Non-Negotiable
Myeloma kidney is the rule, not the exception. Most myeloma patients have some degree of renal impairment from light chain deposition, hypercalcemia episodes, dehydration, and years of nephrotoxic therapy. Every medication must be reviewed for renal dosing. Morphine accumulates in renal failure — switch to hydromorphone or oxycodone. NSAIDs are absolutely contraindicated. Gabapentin accumulates — reduce dose aggressively. Zoledronic acid requires GFR >30 — use denosumab if below. When in doubt, start at 50% of standard dose and titrate slowly.
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Hydromorphone | Opioid / Bone Pain (preferred in renal failure) | 0.2–0.4 mg SQ q4h; 2 mg PO q4h | Preferred opioid in myeloma with renal failure — less metabolite accumulation than morphine. Titrate carefully. ⚠ Avoid morphine if GFR <30 — M6G accumulation causes myoclonus and sedation.[30] |
| Oxycodone | Opioid / Bone Pain (mild-moderate renal impairment) | 5 mg PO q4–6h; reduce 25–50% if GFR <30 | Reasonable alternative in mild-moderate renal impairment. Avoid extended-release formulations in rapidly changing renal function. Monitor closely. |
| Dexamethasone | Corticosteroid / Bone pain, hypercalcemia, anti-myeloma, appetite | 4–8 mg PO/IV daily | The single most versatile comfort drug in myeloma. Reduces bone pain via anti-inflammatory and anti-myeloma effects. Treats hypercalcemia. Stimulates appetite. Anti-emetic. Continue even in final weeks. Taper if stopping — adrenal suppression likely after chronic use.[31] |
| Denosumab | RANKL inhibitor / Bone protection + hypercalcemia | 120 mg SQ monthly | Preferred over zoledronic acid in GFR <30. No renal dose adjustment. Reduces skeletal-related events. Also treats hypercalcemia of malignancy. Fracture prevention is comfort care.[22] |
| Gabapentin (renally adjusted) | Neuropathic agent / Bortezomib/thalidomide neuropathy | GFR >60: 300 mg TID; GFR 30–60: 200 mg BID; GFR <30: 100 mg daily–TID | ⚠ Accumulates in renal failure — MUST reduce dose. Essential for neuropathic bone pain and CIPN. Start low, titrate slowly. Monitor for sedation and ataxia as markers of accumulation.[32] |
| Pregabalin (renally adjusted) | Neuropathic agent / Alternative to gabapentin | GFR >60: 75 mg BID; GFR 30–60: 75 mg daily; GFR <30: 25–50 mg daily | Similar renal dose adjustment requirements. May be better tolerated than gabapentin in some patients. Once-daily dosing possible in renal impairment.[32] |
| Midazolam | Benzodiazepine / SCC emergency, terminal agitation | 2.5–5 mg SQ PRN | Must be at the bedside for any myeloma patient with vertebral disease. Spinal cord compression emergency: immediate dexamethasone + midazolam for distress. Also for terminal agitation and refractory symptoms. Have drawn and labeled.[30] |
| Haloperidol | Antipsychotic / Nausea, delirium, agitation | 0.5–2 mg PO/SQ q4–8h | First-line for nausea from metabolic causes (hypercalcemia, uremia). Effective for delirium and agitation. Low renal clearance — relatively safe in myeloma kidney. Avoid in severe QTc prolongation. |
| Ondansetron | 5-HT3 antagonist / Nausea | 4–8 mg PO/SQ q8h | For multifactorial nausea. Constipating — add bowel regimen. No significant renal adjustment needed. Safe adjunct to haloperidol if monotherapy insufficient. |
| NS Hydration (SQ) | Fluid / Hypercalcemia, dehydration | 500–1500 mL NS SQ over 4–12 hours | Subcutaneous hydration for hypercalcemia symptom management and dehydration. Hospice-appropriate. Can be taught to caregivers for home administration.[29] |
| Lidocaine 5% patch/gel | Topical analgesic / Neuropathic pain | 1–3 patches to affected area 12h on/12h off; or gel PRN | No systemic absorption concerns. Safe in renal failure. Apply to neuropathic areas (hands, feet) for localized neuropathic pain relief. Can be used alongside systemic neuropathic agents. |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h PRN | Reduces terminal secretions without CNS effects. Preferred over hyoscine in conscious patients. Minimal renal concerns at palliative doses. |
🌿 Symptom Management Decision Tree — Multiple Myeloma
Evidence-based · Hospice-adapted · Renal-adjustedSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves for Myeloma
- Midazolam 5 mg/mL: Drawn and labeled — for spinal cord compression distress, terminal agitation, and catastrophic pain. Must be at bedside for any patient with known vertebral lesions.
- Dexamethasone 4 mg tablets or injectable: Spinal cord compression protocol — 10 mg IV/SQ stat, then 4 mg q6h. Also for hypercalcemia and refractory bone pain flares.
- Hydromorphone 2 mg/mL injectable: PRN breakthrough — preferred over morphine in renal failure. Pre-drawn, pre-labeled with PRN dose calculated.
- Haloperidol 5 mg/mL: For nausea from hypercalcemia/uremia and for delirium management. 0.5–1 mg SQ q4h PRN.
- Glycopyrrolate 0.2 mg/mL: Terminal secretions management.
Clinician Pointers
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of managing myeloma at end of life.
1
Hypercalcemia is the most commonly missed treatable symptom
It presents as confusion, nausea, constipation, polyuria, and profound fatigue — all of which can be attributed to "disease progression." When your myeloma patient "seems worse" without an obvious reason, check the calcium before attributing decline to dying. Mild to moderate hypercalcemia (11–13 mg/dL) is treatable with IV or subcutaneous hydration plus denosumab, and the clinical improvement can be dramatic within 48–72 hours. Do not let treatable hypercalcemia masquerade as the dying process.[27]
2
Bortezomib and thalidomide neuropathy persists indefinitely
This is often the dominant symptom at hospice enrollment. Patients who received these agents years ago may have severe peripheral neuropathy with burning, allodynia, and loss of fine motor function. This neuropathy does not improve after treatment stops. Gabapentin (renally adjusted) and topical agents (lidocaine gel, capsaicin) are the primary tools. Do not escalate opioids alone for pure neuropathic pain without adding a neuropathic agent — opioids are poorly effective for neuropathic pain in isolation.[32]
3
Spinal cord compression is a preventable crisis
Know the vertebral lesion locations from the imaging. Assess neurological status at every visit — ask about leg weakness, numbness, bowel and bladder function. Have the dexamethasone protocol written in the care plan before you need it (10 mg stat, then 4 mg q6h). The family who was told what to watch for will call you. The family who was not will call 911. Teach the warning signs explicitly at the intake visit.[33]
4
NSAIDs are absolutely contraindicated
This includes over-the-counter ibuprofen, naproxen, and aspirin at analgesic doses. Every myeloma patient on your caseload should have this contraindication written in their allergy or medication alert list. Educate the family explicitly — they may have been using OTC pain relievers for years without understanding the risk. A single dose of ibuprofen in a myeloma patient with borderline GFR can precipitate acute kidney failure.[30]
5
The treatment-exhaustion conversation requires specific language
These patients have heard "there's one more thing to try" many times. Do not use "there's nothing more we can do." Instead: "The question is no longer whether there is another treatment — the question is whether the treatments that remain would help you more than they would hurt you. What I can tell you is that what we are doing now — managing your pain, keeping you comfortable, giving you time with your family — that is something. And we are very good at it." Acknowledge the years of fighting. Validate every prior decision. Then be honest.
6
Racial equity is a clinical responsibility in myeloma
Black Americans with myeloma have often received fewer lines of therapy, later access to novel agents, and less access to transplant than white patients with identical disease. By the time they reach hospice, the cumulative effect of those disparities may have shortened their trajectory. The hospice clinician cannot undo that history — but must provide care that is unconditionally excellent, must advocate fiercely for adequate pain management (Black patients are systematically undertreated for pain across all diagnoses), and must never allow implicit bias to influence clinical decisions about opioid dosing, intervention intensity, or goals-of-care conversations.[11]
7
Dialysis decisions are a primary clinical conversation
Many myeloma patients reach hospice on dialysis or with dialysis being considered. The goals-of-care conversation about dialysis continuation must be explicit: What is the goal of dialysis? Is it extending life, managing symptoms (uremia), or both? What is the quality of life on dialysis days vs. off days? What happens if dialysis is discontinued? Uremia from dialysis cessation in myeloma typically progresses to somnolence and coma over 1–2 weeks — often a peaceful trajectory. This is a conversation, not a decision made in isolation.[6]
"The myeloma patient who arrives at your door has been through more treatment than you can imagine. They've had more bone marrow biopsies than most oncologists have ordered. They know the names of every drug they've taken and what each one did to them. Respect that expertise. Learn from it. And then earn their trust by managing the bone pain they've been told is 'just part of the disease' as though it matters — because it does."
— Waldo, NP · Terminal2
Psychosocial & Spiritual Care
The long-haul grief of myeloma, treatment identity loss, neuropathy's toll on dignity, steroid psychiatric effects, and the caregiver who has been at this for a decade.
The long-haul grief. Multiple myeloma patients have often been living with this disease for 5, 7, or 10 years by the time they reach hospice. They have normalized cycles of treatment, response, plateau, and relapse so many times that hospice may feel like just one more phase rather than a transition to dying. The hospice clinician must gently but clearly anchor the conversation in the reality of this transition while honoring the extraordinary endurance the patient has already demonstrated. Say: "You have fought harder and longer than most people will ever understand. And what we're doing now — focusing entirely on your comfort — is not the opposite of fighting. It is the next thing."[34]
Treatment identity loss. Many myeloma patients have built their identity around fighting. Their social connections center on their oncology team, their infusion center relationships, and the structure that active treatment provides. Monthly blood draws, clinic visits, pharmacy calls — these defined their weeks for years. The loss of treatment is not just a medical loss — it is a social and identity loss. The infusion nurses who knew their name, the parking lot they walked through, the routine that gave structure to living with cancer — all of that is gone. Name it explicitly and help them find a new frame.[34]
Myeloma-Specific Psychosocial Dimensions
Neuropathy & Body Image
Severe peripheral neuropathy changes a person's relationship with their own hands and feet. Patients who can no longer button shirts, hold pens, pick up grandchildren, or feel the ground under their feet experience a cumulative loss of self that is often unaddressed. Ask directly about neuropathy's impact on daily activities and dignity. "What does the numbness in your hands keep you from doing that matters to you?" This is not a medical question — it is an identity question. And it deserves a direct answer and targeted intervention (topical agents, adaptive devices, occupational therapy referral).
Steroid-Related Psychiatric Effects
Patients who have been on long-term dexamethasone develop mood instability, insomnia, hyperactivity, irritability, and sometimes frank psychiatric symptoms — steroid psychosis, mania, severe depression. These may persist even after steroid dose reduction because of prolonged HPA axis disruption. Address them as treatment side effects, not character flaws. Families need to hear: "The irritability and mood swings your loved one has been having — that is the medication, not the person you know. It gets better when we can reduce the dose, and we can manage it."[31]
Racial Equity in End-of-Life Care
Black Americans who reach end-stage myeloma after receiving fewer lines of therapy, later access to transplant, and delayed access to novel agents carry a specific injustice in their trajectory. The hospice clinician cannot undo that history but must provide care that is unconditionally excellent. This means: advocate fiercely for adequate pain management (studies consistently show Black patients receive less opioid analgesia than white patients with identical pain scores), ensure goals-of-care conversations are free of assumptions about preferences based on race, and create space for the anger that may accompany the realization that the system failed them before you arrived.[11]
Caregiver Exhaustion
Myeloma caregivers are the most exhausted caregivers in hospice. They have been caregiving for years — through stem cell transplant recovery, through infusion days, through steroid mood swings, through pathologic fractures, through ICU admissions for infection. By the time hospice enrolls, the caregiver may be running on reserves they depleted years ago. Screen for caregiver depression and burnout at enrollment using a single direct question: "How are you holding up — honestly?" Offer respite care proactively, not reactively. Connect with social work and chaplaincy for caregiver-specific support. The caregiver's collapse is a clinical emergency with direct impact on patient care.[35]
Clinical Pearl
"Myeloma patients have been preparing for this transition for years — they just didn't know it. Every relapse was a rehearsal. Every treatment discussion was a goals conversation in disguise. The hospice transition is not a sudden event — it is the culmination of a decade of accumulated understanding. Your job is to help them see that what they already know about their disease is the foundation for the peace they're looking for."
"The hardest myeloma patient I ever cared for wasn't hard because of the bone pain or the calcium levels. She was hard because she couldn't reconcile that the fight was over when fighting was the only thing that had kept her going for eight years. She didn't need a better drug. She needed someone to say: 'You did everything right. Every single decision. And what you're doing now — letting us take care of the pain — that's still doing it right.' That's what broke through."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside. Written for the people who have been caregiving through years of myeloma treatment.
You have been on this journey with your loved one for a long time. You have watched them go through treatments, side effects, blood draws, and hospital visits for years. You know this disease in a way that no medical textbook captures — because you've lived it beside them. Now that the focus has shifted entirely to comfort, your role is more important than ever. You are not just watching — you are the most important member of the care team. This guide will help you know what to expect, what to do, and when to call us.
What You May See
- Severe bone pain — especially in the back, ribs, and hips: This is the most common and most treatable symptom. Do not wait to report pain that is not controlled. Pain medication should keep your person comfortable — if it's not working, call the nurse. There is always a next step.
- Confusion, nausea, constipation, and extreme thirst or frequent urination: This combination may mean the calcium level is too high (hypercalcemia). This is treatable and your nurse needs to know immediately. Don't assume it's "just the disease getting worse" — it may be something we can fix in a day or two.
- Back pain that is suddenly much worse, or any new leg weakness, numbness, or change in bladder or bowel control: This may be pressure on the spinal cord. Call the nurse immediately — this is urgent. The team has a plan for this, but we need to know fast.
- Frequent infections — colds, pneumonias, shingles, sinus infections: The myeloma suppresses the immune system. Infections come easily and may require treatment. Report fevers (>100.4°F) promptly.
- Tingling, burning, or numbness in the hands and feet: This is neuropathy from prior treatment. It is manageable with medication and comfort measures. Warm socks and gloves help.
- Profound fatigue and sleeping more: This is the disease affecting the bone marrow and it is expected. Let your person rest when they need to.
How You Can Help
- Never give ibuprofen, naproxen, or aspirin for pain: These are dangerous for the kidneys in myeloma. Use only acetaminophen (Tylenol) unless the nurse has prescribed something else. Ask before giving anything over-the-counter.
- Be very careful with physical activity and transfers: The bones are fragile. No twisting or sudden movements. Use a gait belt if recommended. Report any fall immediately — even if the person seems fine afterward. A fracture may not be obvious right away.
- Know the spinal cord compression warning signs: Sudden worse back pain with leg weakness or numbness is an urgent call. Your nurse reviewed this with you — keep the instructions posted where you can find them.
- Report confusion or sudden behavior change immediately: This may be the calcium level and it is treatable. Don't wait until the next scheduled visit.
- Keep the environment warm for neuropathy: Cold worsens the burning and numbness in hands and feet. Warm socks, gloves, and blankets for comfort.
- Be patient with the long journey — and with yourself: You have been caregiving for years. Your exhaustion is real and it is valid. Call us when you need support — not just when the patient does. We are here for you too.
📞 Call the nurse immediately if you see:
New or sudden back pain with any leg weakness, numbness, or bladder/bowel changes (possible spinal cord compression — urgent). Sudden confusion, severe nausea, or extreme thirst with very frequent urination (possible high calcium — treatable). Fever over 100.4°F (infection — may need treatment). Any fall — even if the person seems fine (hidden fracture risk). Severe pain not relieved by prescribed medications within 1 hour. Sudden difficulty breathing. Do not wait. Call us. Day or night. That is what we are here for.
🙏 You have been doing this for a long time. Longer than most people could. The fact that your person has made it this far is in no small part because of you — your advocacy, your presence, your refusal to let them face this alone. What you are doing right now, being here, is the most important medicine we have. Research consistently shows that patients with present, informed family members have better pain control, less anxiety, and more peace. You are not just watching — you are treating.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
- 01Check the calcium when your myeloma patient "seems worse." I cannot say this loudly enough. Confusion, nausea, profound fatigue, constipation without obvious cause — that is hypercalcemia until proven otherwise. It is treatable. A patient who looks like they are dying on Tuesday may be talking to you, sitting up in bed, eating lunch by Friday if you check the calcium and treat it with hydration and denosumab. I have seen this more times than I can count. Do not miss this. The family that loses a treatable week because nobody checked a calcium level — that is on us. Not the disease. Us.
- 02Spinal cord compression is a preventable crisis in myeloma. At your intake visit — before you leave the house — you need to know every vertebral level with a lytic lesion. Write them down. Put them in the care plan. Then teach the family: "If the back pain suddenly gets much worse, or if you notice any new weakness in the legs, any numbness, or any change in bladder or bowel control — call us immediately. Do not wait. Do not call in the morning." Have the dexamethasone protocol written and ready: 10 mg stat, then 4 mg q6h. The family who was told what to watch for calls you. The family who was not calls 911. Every time.
- 03NSAIDs are absolutely contraindicated and I put this at number three because I still see it happen. Write it in the chart. Say it to the family. Put it on the allergy list. Print it out and tape it to the refrigerator if you have to. OTC ibuprofen in a myeloma patient with a GFR of 35 can precipitate acute kidney failure within days. These patients may have been using it for years without understanding the risk — they bought it at the drugstore, it's "just Advil." Stop it today. Replace it with acetaminophen and talk to me about the bone pain, because that's what they're actually trying to treat and we have better tools.
- 04Renal dose adjustment is not optional — it is the single most important clinical discipline in myeloma hospice care. Every medication you prescribe must be reviewed for renal clearance. Morphine accumulates and causes myoclonus — the family calls panicking about "seizures" at 2 AM and the answer is that you should have used hydromorphone. Gabapentin accumulates and causes sedation so severe the family thinks their person is dying — the answer is you should have started at 100 mg in that GFR-25 patient instead of 300 mg. Check the GFR. Adjust the dose. Check it again when the creatinine changes. This is not optional. This is how you practice safely in myeloma.
- 05Bortezomib and thalidomide neuropathy does not go away when treatment ends. Full stop. That burning in the hands and feet, that numbness, that loss of fine motor control — it is permanent in most patients, and it is often the thing that causes more daily suffering than the bone pain. These patients stopped their PI or IMiD years ago and the neuropathy stayed. It requires targeted treatment: gabapentin (renally adjusted, I cannot stress that enough), topical lidocaine patches or gel, and acupuncture if you can get it. Do not just escalate opioids for pure neuropathic pain. Opioids barely touch neuropathic pain without a neuropathic co-agent. Add the right drug. Do the right thing.
- 06Denosumab over zoledronic acid in any myeloma patient with GFR under 30. Period. This is not a preference — it is a clinical requirement. Zoledronic acid is nephrotoxic and requires adequate renal function. Denosumab requires no renal adjustment, is given subcutaneously, treats both bone disease and hypercalcemia, and is the right bone-modifying agent for almost every end-stage myeloma patient you will encounter. I have it in almost every myeloma care plan I write. Fracture prevention is comfort care. Say it until you believe it, because your patients already do — they know what a fracture feels like.
- 07Dexamethasone is the Swiss Army knife of myeloma comfort care. Low-dose dex — 4 mg daily — reduces bone pain through its anti-inflammatory effect, has direct anti-myeloma activity (so it can slow disease progression even as a comfort measure), treats hypercalcemia, stimulates appetite, improves energy, and reduces nausea. I continue it in almost every myeloma patient through the final weeks. When you do taper it — and you will eventually need to — do it slowly. These patients have been on steroids for years. Their adrenal glands have forgotten how to work. Taper by 1 mg every 3–5 days at minimum. Abrupt cessation causes adrenal crisis.
- 08The long-haul grief of myeloma is unlike any other cancer I've worked with. These patients have been living with cancer for a decade. They've normalized it. Their identity is built around being a "myeloma fighter." Their social life revolves around the infusion center. When you take away the treatment, you are taking away the structure, the community, and the purpose that has organized their life for years. That grief is not about dying — it is about losing the only life they've known since diagnosis. Name it. Say: "I can see how much you've lost — not just the treatment, but everything that came with it." That sentence alone changes the conversation.
- 09Racial equity in myeloma is not theoretical — it is the patient in front of you. Black Americans get myeloma at twice the rate and are less likely to have received transplant, less likely to have been enrolled in clinical trials, and less likely to have had access to the novel agents that extend life. The data shows that when access is equal, outcomes are equal or better. That means the disparity you are inheriting at hospice enrollment is a systems failure, not a biological inevitability. Your response: advocate harder for pain management (Black patients receive fewer opioid prescriptions across all diagnoses), ensure every comfort intervention is offered regardless of assumptions, and be the clinician who does it right — even if others before you did not.
- 10At the end of the day, this work is about presence. Myeloma patients have been surrounded by medical professionals for years — oncologists, nurses, pharmacists, transplant teams, clinical trial coordinators. They have been poked, scanned, infused, and monitored more than most people can imagine. What they need from you is not another medical opinion. What they need is someone who sits down, looks them in the eye, and says: "I'm here. Not to fix this. Not to try one more thing. Just to be here, and to make sure you are not in pain, and to make sure your family knows what to do. That is enough. You are enough." Be there. That's the whole job.
— Waldo, NP
References
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.
2
Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022;97(8):1086-1107.
3
Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8(1):7.
4
LeBlanc TW, El-Jawahri A. Integrating palliative care in the management of multiple myeloma. Hematology Am Soc Hematol Educ Program. 2020;2020(1):578-584.
5
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548.
6
Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544-1557.
7
Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962.
8
Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-1128.
9
Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-1369.
10
Went M, Sud A, Försti A, et al. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun. 2018;9(1):3707.
11
Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116(25):5501-5506.
12
Institute of Medicine. Veterans and Agent Orange: Update 2014. Washington, DC: National Academies Press. 2016.
13
Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777). Lancet. 2017;389(10068):519-527.
14
Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma (PERSEUS). N Engl J Med. 2024;390(4):301-313.
15
Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma (IFM 2009). N Engl J Med. 2017;376(14):1311-1320.
16
Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma (POLLUX). N Engl J Med. 2016;375(14):1319-1331.
17
Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma (ASPIRE). N Engl J Med. 2015;372(2):142-152.
18
Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma (KarMMa). N Engl J Med. 2021;384(8):705-716.
19
Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma (MajesTEC-1). N Engl J Med. 2022;387(6):495-505.
20
Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma (STORM). N Engl J Med. 2019;381(8):727-738.
21
Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX). Lancet. 2010;376(9757):1989-1999.
22
Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370-381.
23
Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer (Cancer Patient Fracture Evaluation — CAFE). Lancet Oncol. 2011;12(3):225-235.
24
Rades D, Hoskin PJ, Stalpers LJ, et al. Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. Int J Radiat Oncol Biol Phys. 2006;64(5):1452-1457.
25
Chapel H, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet. 1994;343(8905):1059-1063.
26
Lu W, Rosenthal DS. Acupuncture for cancer pain and related symptoms. Curr Pain Headache Rep. 2013;17(3):321.
27
Goldner W. Cancer-related hypercalcemia. J Oncol Pract. 2016;12(5):426-432.
28
Bradt J, Dileo C, Magill L, Teague A. Music interventions for improving psychological and physical outcomes in cancer patients. Cochrane Database Syst Rev. 2016;(8):CD006911.
29
Bruera E, Sala R, Rico MA, et al. Effects of parenteral hydration in terminally ill cancer patients: a preliminary study. J Clin Oncol. 2005;23(10):2366-2371.
30
Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497-504.
31
Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361-1367.
32
Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941-1967.
33
Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643-648.
34
Nipp RD, El-Jawahri A, Fishbein JN, et al. The relationship between coping strategies, quality of life, and mood in patients with incurable cancer. Cancer. 2016;122(13):2110-2116.
35
Molassiotis A, Wilson B, Blair S, Howe T, Cavet J. Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners. Psychooncology. 2011;20(1):88-97.
36
Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107-113.
37
San-Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003). Lancet Oncol. 2013;14(11):1055-1066.
38
Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma (CARTITUDE-1). J Clin Oncol. 2023;41(6):1265-1274.
39
Dimopoulos MA, Palumbo A, Corradini P, et al. Safety and efficacy of carfilzomib vs bortezomib in patients with relapsed and refractory multiple myeloma (ENDEAVOR). Lancet Oncol. 2016;17(1):27-38.
40
Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95). Lancet Haematol. 2020;7(6):e456-e468.
41
Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301-310.
42
Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412-5417.
43
Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-2074.
44
McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279-3289.
45
Costa LJ, Brill IK, Omel J, et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017;1(4):282-287.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.